As mentioned previously, hospitalized COVID-19 patients who experienced new neurological symptoms during admission had elevated plasma levels of UCH-L1, p-tau 181, and NfL, when compared to the control group consisting of non-COVID AD patients (Frontera et al., 2022). The gene discussed is UCHL1; the disease is Alzheimer disease.